ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1517

Comparing Deep Neural Network to Modified Rodnan Skin Score in a Trial for Belumosudil in Systemic Sclerosis Patients

Baran Gunes1, Lucy Duran Camacho1, Shawn Cowper2, Gauri Panse2, Elizabeth Bundschuh3, Alyssa Williams4, Nicolas Page5, Mary Karns6, Kathleen Aren6, Niki Pradhan7, Elana Bernstein8, Sarah Fantus9, Elizabeth Volkmann10, Heather Bukiri10, Chase Correia11, Francis Wilson1, Seamus Mawe12, J. Matthew Mahoney13, Monique Hinchcliff14 and Rui Wang15, 1Yale University School of Medicine, New Haven, CT, 2Yale School of Medicine - Dermatopathology, New Haven, CT, 3Yale University School of Medicine, New York, NY, 4Yale University School of Medicine, Winchester, MA, 5Yale University School of Medicine, Salem, CT, 6Northwestern University Division of Rheumatology, Chicago, IL, 7Columbia University Irving Medical Center, New York, NY, 8Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, 9Kansas City Physician Partners- Center for Rheumatic Disease, Kansas City, MO, 10University of California Los Angeles, Los Angeles, CA, 11Riverside Medical Group, Hampton, VA, 12The Jackson Laboratory, Bar Harbor, ME, 13Jackson Laboratory, Bar Harbor, ME, 14Yale School of Medicine, Westport, CT, 15Sanofi, Cambridge, MA

Meeting: ACR Convergence 2023

Keywords: Biomarkers, clinical trial, Fibrosing syndromes, skin, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1513–1533) Systemic Sclerosis & Related Disorders – Clinical Poster II: Clinical Trial, Treatment & Intervention

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: We previously published a proof-of-principle study demonstrating the potential utility of computer vision (Deep Neural Network/DNN) methods applied to stained skin biopsy sections from patients with systemic sclerosis (SSc) as a novel skin outcome. The present study compared the ‘DNN-Fibrosis Score’ with histopathologic and modified Rodnan Skin Score (mRSS) changes for participants enrolled in a clinical trial.

Methods: Ten adults with early (≤ 6 y) diffuse cutaneous SSc (15 ≤ mRSS ≤ 35) in an open-label belumosudil (ROCK2 inhibitor, 200 mg PO BID) trial had mRSS and two, 4mm, dorsal arm skin biopsies performed at weeks 0, 24, and 52. Biopsies were stained with CD34, CD3, CD8, alpha smooth muscle actin (ASMA), H&E, and trichrome. Two blinded dermatopathologists assessed biopsies for 16 histopathological parameters important in SSc (Van Praet JT et al., 2011). CD3+, CD8+ were counted, and visual analogue scales (VAS) were used to score CD34, ASMA, and relative SSc severity on H&E and trichrome (Fig. 1). A previously developed DNN algorithm (AlexNet) was applied to trichrome-stained images to generate a ‘DNN-Fibrosis Score’ as previously reported. ‘DNN-Fibrosis Scores’ were compared to mRSS using a linear regression model and Spearman correlation. Histopathologic parameters were compared to mRSS or DNN Fibrosis-Scores using logistic regression models. A p≤0.05 was considered significant.

Results: Five patients had paired biopsies (Fig. 2). The median (interquartile range/IQR) mRSS change between 0 – 52W was -2.5 (-11 to 7.5) while the median (IQR) DNN-Fibrosis Score change (W0 – last follow-up) was -6 (-10.5 to 6.5) (Fig. 3). Of the histopathological scores, subcutaneous (SC) fat loss (p = 0.012), eccrine entrapment (p = 0.008), % CD8+ among CD3+ cells (p = 0.006) changed most during treatment. The correlation between mRSS and DNN-Fibrosis Score for the 5 paired biopsies was 0.18 [at higher mRSS, i.e. 25-51, the correlation was weaker] (Fig. 3b). Per 1-unit mRSS increase, the histopathological parameter odds ratios (OR); p-values were: telangiectasia =2.01; 0.001, perivascular CD3+ =1.03; 0.015, and % of CD8+ among CD3+ =1.08; 0.031 (Fig. 3c). Likewise, per 1-unit DNN Fibrosis-Score increase, OR; p-values for histopathological parameters were: hyalinized collagen =1.1; 0.00033, SC fat loss =1.47; 0.00033, intima wall =1.21; 0.005, and eccrine entrapment =1.14; 0.046 (Fig. 3c).

Conclusion: In this novel exploratory analysis, the DNN-Fibrosis Score exhibited sensitivity to histopathologic changes. The weak correlation between mRSS and DNN-Fibrosis Score contrasted with our previous findings. We note that predicted DNN-Fibrosis Scores tended to be lower for participants with higher mRSS ( >25). We attribute this divergence to batch effects from staining protocols between our published and our current analysis which may be overcome with analyses of larger cohorts. However, despite the weak correlation with mRSS, the DNN-Fibrosis Score significantly correlated with a set of histopathological variables that were distinct from those correlated with mRSS, including hyalinized collagen, SC fat loss, intima wall thickness, and eccrine entrapment.

Supporting image 1

Figure 1. Histopathology assessment. a. Visual Analog Scale keys. b. Composite visual analog scales (from normal to maximum).

Supporting image 2

Figure 2. Stained sections from the 3 subjects with the largest mRSS changes between W0, 24 and 52 (40x).

Supporting image 3

Figure 3. Belumosudil open-label trial results. a. Subject’s mRSS W0 to last follow-up. b. Scatter plot of DNN Fibrosis Score and mRSS (p = 0.125). c. Ordinal logistic regression (95% CI) comparing DNN Fibrosis Score to 16 scored histologic parameters.


Disclosures: B. Gunes: None; L. Duran Camacho: None; S. Cowper: None; G. Panse: None; E. Bundschuh: None; A. Williams: None; N. Page: None; M. Karns: None; K. Aren: None; N. Pradhan: None; E. Bernstein: Boehringer Ingelheim, 2, 5, Kadmon, 5, Pfizer, 5; S. Fantus: None; E. Volkmann: Boehringer-Ingelheim, 2, 5, 6, CSL Behring, 2, GlaxoSmithKline, 2, Horizon, 5, Prometheus, 5, Roche, 2; H. Bukiri: None; C. Correia: None; F. Wilson: Amgen, 5, AstraZeneca, 5, Vifor Pharma, 5; S. Mawe: None; J. Mahoney: None; M. Hinchcliff: Boehringer-Ingelheim, 5, Kadmon, 5; R. Wang: None.

To cite this abstract in AMA style:

Gunes B, Duran Camacho L, Cowper S, Panse G, Bundschuh E, Williams A, Page N, Karns M, Aren K, Pradhan N, Bernstein E, Fantus S, Volkmann E, Bukiri H, Correia C, Wilson F, Mawe S, Mahoney J, Hinchcliff M, Wang R. Comparing Deep Neural Network to Modified Rodnan Skin Score in a Trial for Belumosudil in Systemic Sclerosis Patients [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/comparing-deep-neural-network-to-modified-rodnan-skin-score-in-a-trial-for-belumosudil-in-systemic-sclerosis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparing-deep-neural-network-to-modified-rodnan-skin-score-in-a-trial-for-belumosudil-in-systemic-sclerosis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology